Form 4: Allakos Director Paul Edward Walker Disposes of Shares and Options in Merger with Concentra Biosciences

Director Paul Edward Walker reports the disposal of Allakos Inc. shares and stock options due to the merger agreement with Concentra Biosciences, receiving $0.33 per share.

Summary

• Paul Edward Walker, a director of Allakos Inc., filed a Form 4 detailing changes in beneficial ownership.
• The report indicates the disposal of 2,760,860 shares of common stock indirectly held through NEA 16 and 3,386,400 shares indirectly held through NEA 18 VGE.
• These disposals occurred on May 15, 2025, as a result of the merger agreement with Concentra Biosciences, where shares were exchanged for $0.33 in cash per share.
• Walker also reported the disposal of multiple stock options with varying exercise prices and expiration dates, all cancelled without consideration due to the merger agreement.
• Walker disclaims beneficial ownership of the securities held by NEA 16 and NEA 18 VGE, except to the extent of his pecuniary interest.
• The merger agreement was dated April 1, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the low share price received in the merger and the cancellation of stock options, indicating a poor outcome for the reporting person and potentially other shareholders.

Negatives

• The disposal of shares and cancellation of stock options indicate a significant change in Walker's investment in Allakos.
• The merger resulted in shareholders receiving only $0.33 per share, which may be viewed negatively by investors who expected a higher valuation.

Risks

• The merger with Concentra Biosciences may not yield the anticipated benefits for former Allakos shareholders.
• The cancellation of stock options represents a loss of potential future gains for the reporting person.

Future Outlook

The document does not contain specific forward-looking statements beyond the completion of the merger with Concentra Biosciences.

Industry Context

Mergers and acquisitions in the biotechnology industry are common, often driven by the desire to consolidate resources, acquire promising drug candidates, or achieve economies of scale. This transaction reflects a strategic shift for Allakos, potentially indicating a change in its focus or direction.

Comparison to Industry Standards

• It is difficult to compare this specific transaction to industry standards without knowing the specific reasons for the merger and the valuations of comparable companies.
• Mergers in the biotech industry often involve premiums paid to shareholders, but the $0.33 per share suggests a distressed situation or a lack of competing offers.
• Comparable companies that have been acquired in the past include...
• However, without more information, it's challenging to provide a detailed comparison.

Stakeholder Impact

• Shareholders received $0.33 per share as a result of the merger.
• Employees may experience changes in their roles or employment status following the merger.
• The merger could impact the company's relationships with suppliers and customers.

Key Dates

Keywords

Form 4, Allakos, Walker, Merger, Concentra Biosciences, Beneficial Ownership, Stock Options, Share Disposal